Avivagen, Inc. · OTC:VIVXF
Avivagen — Banff Conference 2021
24 slides from Avivagen's conference presentation, August 2021
Slide 1: Banff Conference
BANFF CONFERENCE VIV:TSXV VIVXF:OTCQB AUGUST 2021 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation includes certain forward-looking statements that are based upon current expectations of management, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements conta
Slide 3: Avivagen: Living Your Best Life!
AVIVAGEN LIVING YOUR BEST LIFE! 3
Slide 4: Investment Summary
Investment Summary Enhancing Overall Health by boosting the Immune System while Reducing Inflammation Attractive Business Model: once the customer adopts, we are fully integrated with a recurring, increasing revenue profile Record sales contract signed in Mexico New sales in South East Asia Expandin
Slide 5: Primary Objectives
Primary Objectives Dramatic Increase of Overall Sales Expanding Geographic Reach in All Three Verticals Deepening and Solidifying the Scientific community’s awareness and acceptance Formation of New Partnerships 5
Slide 6: What Makes OxC-beta Different?
What Makes OxC-beta™ Different? What it is: • A breakthrough, patent protected health support product This could be What it does: like the • Supports Immune Defenses while also discovery of a • Reducing Inflammation new vitamin Why it matters: • Supports optimal health of all living beings • Accessi
Slide 7: Targeting Three Distinct Markets
Targeting Three Distinct Markets OxC-beta™ OxC-beta™ OxC-beta™ For For For Livestock Human Health Companion Animal 1.2 Billion Tonne Annual $90 Billion U.S. Market $635 Million Worldwide Worldwide Market Market (Rapid sales growth (Launched Feb 1st, 2021) phase) 201 • Each Vertical Represents a Larg
Slide 8: Livestock Feed Market
Livestock Feed Market | VIV es lagen 8
Slide 9: Worldwide Purchase Orders of OxC-beta to date
Worldwide Purchase Orders of OxC-beta™ to date Purchases of OXC-BETA™ • First commercial customer 80,000 in Philippines, 2017 70,000 60,000 • Commercial customers followed by Thailand and Kilograms 50,000 Taiwan 40,000 30,000 • Mexico special case: First 20,000 sale in September 2020, 10,000 followe
Slide 10: Proven Efficacy – Again and Again
Proven Efficacy – Again and Again • Reduced bacteria • Reduced somatic cell count • Increased protein content of milk 40+ Clinical and Field trials • Improved gut health • Reduced E.coli • Better maternal, piglet health • Improved performance • Reduced C. perfringens • Improved performance Strong Co
Slide 11: Supporting Expansion of Approved Markets
Supporting Expansion of Approved Markets Tonnes per 1.2B year of feedstock “Approved” and “In Progress” >50% covers more than 50% of our total addressable market Approved In progress 11
Slide 12: Published Scientific Papers in Highly Respected Scientific Journals
Published Scientific Papers in Highly Respected Scientific Journals 12
Slide 13: Strategic Growth Plan
Strategic Growth Plan Livestock Market 1 Capitalize on current partnerships, with commercial and research field trials on-going Driving Market 2 Gain regulatory approval in additional countries Share and Revenue Growth 3 Add distribution deals in approved markets 13
Slide 14: Recent Developments
Recent Developments Addition of Mr. Lesley Nernberg as a technical sales and marketing consultant, with primary focus on Vietnam, Indonesia and South Korea MEXICO: 64.5 tonne purchase order, May 2021; 6 tonne purchase order, January 2021; 10 tonne purchase order, September 2020 Expansion of Meyenber
Slide 15: Competitive Landscape
Competitive Landscape Probiotics/Prebiotics: • Mixed efficacy, storage requirements OxC-beta™ Essential Oils: Represents a • Old Technology, mixed efficacy, Next Generation compliance difficulties Antibiotic Alternative Zinc Oxide: • Environmental issues, banned in many countries 15
Slide 16: Human Health Market
Human Health Market > WIV. Avivagen
Slide 17: Human Wellness, Nutraceutical Opportunity
Human Wellness, Nutraceutical Opportunity $20 Billion On-line U.S. Market Launched on Amazon U.S. Feb 1st, 2021 under Dr. Tobias Beta Blend label Global Opportunity Currently in discussions with potential new partners to expand into international market 17
Slide 18: Companion Animal Market
ch Be. Companion Animal MaKe WIV. Avivagen
Slide 19: OxC-Beta for Companion Animal
OxC-Beta™ for Companion Animal North America • Sales on Amazon • JV with Mimi’s Rock (TSXV:MIMI) Taiwan & Mexico • First health chews sales in Taiwan in 2019 • First sale to pet food manufacturer in Taiwan in 2020 • First health chews sales in Mexico in 2020 Capitalizing on Current Sales Initiatives
Slide 20: Capital Markets Information
Capital Markets Information VIV on TSXV VIVXF on OTCQB Shares outstanding: 56.8M Market capitalization: $19.3M Recent Price: $0.34 per share *As of August 16, 2021 20
Slide 21: Upcoming Milestones
Upcoming Milestones Record Sales Contracts and New Country Approvals Completion of current animal trial studies, with initiation of new ones Continued research on new applications of OxC-beta and anticipated publications New Partnerships and full reassessment of those currently established. 21
Slide 22: Appendix
APPENDIX < Avivagen >
Slide 23: Published Scientific papers
Published Scientific papers Efficacy of polymers from spontaneous carotenoid oxidation in reducing necrotic enteritis in broilers. Poultry Science, 2018 Effects of maternal supplementation with fully oxidised β-carotene on the reproductive performance and immune response of sows, as well as the grow
Slide 24: Investor Presentation • February 2021
Investor Presentation • February 2021 24